YAOTANG BIOLOGY
Yaotang (Shanghai) Biotechnology is a high-tech biotechnology company focusing on developing a new generation of mRNA drugs and gene editing drugs by combining mRNA in vivo delivery technology and gene editing technology. Through the continuous development and optimization of CRISPR, base editing and other new-generation gene editing tools, and innovative improvements to the next-generation mRNA production platform and lipid nanocarrier assembly process, Yaotang Bio is committed to developing treatments for genetic diseases and cardiovascular disease.
YAOTANG BIOLOGY
Social Links:
Industry:
Biopharma Biotechnology
Founded:
2021-07-01
Address:
Minhang, Shanghai, China
Country:
China
Website Url:
http://www.yoltx.com
Status:
Active
Contact:
1-215-226-0086
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
SPF HiChina DNS Alibaba Cloud MailBox
Investors List
Xianfeng Qiyun
Xianfeng Qiyun investment in Angel Round - Yaotang Biology
Official Site Inspections
http://www.yoltx.com
- Host name: 106.15.103.126
- IP address: 106.15.103.126
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Yaotang Biology"
ABOUT YolTech - yoltx.com
YolTech Therapeutics is a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines.See details»
YolTech
YolTech Therapeutics is a pioneering gene editing company dedicated to develop a robust gene editing medicines to treat patients with serious diseases, which has built leading high …See details»
Yaotang Biology - Crunchbase Company Profile
Organization. Yaotang Biology . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Yaotang Bio …See details»
尧唐生物 - yoltx.com
尧唐生物（YolTech Therapeutics）成立于2021年7月，总部位于上海，是一家以创新为驱动的高科技生物技术公司。公司专注于体内基因编辑技术，并通过mRNA-LNP递送系统开发新一代 …See details»
YolTech Therapeutics Administers First Patient Dose in IIT
SHANGHAI, Aug. 22, 2024 /PRNewswire/ -- YolTech Therapeutics, a pioneering clinical-stage gene editing company dedicated to delivering lifelong cures, today announced a major …See details»
Yoltech Therapeutics Co., Ltd. - Drug pipelines, Patents, …
Mar 29, 2025 For more information, please visit: www.yoltx.com SOURCE: YolTech Therapeutics. Gene Therapy Orphan Drug Clinical Result. ... The statistics for drugs in the Pipeline is the current organization and its …See details»
yoltx.com - Company Profile - Tracxn
Yoltx.com - Developer of mRNA and gene editing drugs for multiple diseases. Raised a total funding of $14.1M over 3 rounds from 4 investors. Founded by Yuxuan Wu in the year 2021. …See details»
Landmark Clinical Approval for YOLT-201 Obtained by the NMPA
SHANGHAI, March 4, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developing in vivo gene editing therapies to treat rare genetic diseases, today announced the …See details»
Yoltech Therapeutics Co., Ltd. (尧唐（上海）生物科技有限公司)
Mar 28, 2025 Arbor Biotechnologies, a startup founded by CRISPR pioneer Feng Zhang nine years ago, has closed a $73.9 million Series C financing to bring its first therapy into clinical …See details»
YolTech Therapeutics Receives U.S. FDA Rare Pediatric Disease ...
SHANGHAI, Sept. 4, 2024 /PRNewswire/ -- YolTech Therapeutics, a pioneering gene editing company focused on developing in vivo gene editing medicines, today announced that the …See details»
yoltx.com - 2025 Funding Rounds & List of Investors - Tracxn
Apr 10, 2025 yoltx.com has raised a total funding of $14.1M over 3 rounds from 4 investors. Investors include Decheng Capital, K2VC and 2 others. Their latest funding round was of …See details»
YOLT-202 Receives FDA Orphan Drug Designation - yoltx.com
April 10, 2025 – Shanghai, China — YolTech Therapeutics, a clinical stage biotechnology company developing next-generation in vivo gene editing therapies, today announced that the …See details»
YOLT-204 - Drug Targets, Indications, Patents - Synapse - Patsnap
Mar 20, 2025 For further details about the trial or YolTech’s ongoing programs, please visit [ www.yoltx.com ] or contact [ [email protected] ]. About YOLT-204 YOLT-204 is an off-the-shelf …See details»
尧唐生物（YolTech）完成超亿元A+轮融资 - 创投之家
Nov 30, 2023 全球体内基因编辑和碱基编辑技术开拓者尧唐生物（YolTech）已完成超亿元人民币A+轮融资，由德诚资本领投，广州产投和华方资本跟投。浩悦资本担任本轮独家财务顾问 …See details»
尧唐生物-动脉网 - vbdata.cn
Jul 8, 2021 尧唐（上海）生物科技有限公司成立于2021年，是一家专注于结合mrna体内递送技术和基因编辑技术，开发新一代mrna药物和基因编辑药物的高科技生物技术公司。尧唐生物通 …See details»
【首发】尧唐生物完成超亿元人民币A+轮融资，加速体内基因编辑 …
Nov 30, 2023 动脉网获悉，近日，全球体内基因编辑和碱基编辑技术开拓者尧唐生物已完成超亿元人民币a+轮融资，由德诚资本领投，广州产投和华方资本跟投。浩悦资本担任本轮独家财务 …See details»
LATESTNEWS - yoltx.com
Shanghai, China - March 11, 2025—YolTech Therapeutics, a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines, today …See details»
Tides 速递 | 尧唐生物国内首款基于mRNA-LNP递送的体内基因编辑 …
｜中肽生化内容团队编辑. 2023年12月5日，cde官网显示，尧唐（南京）生物科技有限公司（以下简称“尧唐生物”）自主研发的yolt-201注射液获得ind受理（受理号：cxsl2300837），有望开启 …See details»
YolTech Receives U.S. FDA ODD for YOLT-203 in Treating PH1
Sep 23, 2024 With promising early clinical outcomes, YolTech is also advancing therapies for familial hypercholesterolemia (FH) and primary hyperoxaluria type 1 (PH1). As a company …See details»
Our Company - Lytx
Apr 17, 2025 Combining advanced technology with unmatched industry expertise, we’re setting new benchmarks for fleet safety and operational efficiency. Award-WinningSee details»